Kazuhiko Yoshida

20PUBLICATIONS
23CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersRadiation therapyPanel data analysis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|May 07, 2026
Comparison of clinical outcomes of cabozantinib plus nivolumab and lenvatinib plus pembrolizumab in patients with metastatic renal cell carcinoma.

|Mar 02, 2026
Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma.

Hiroki Ishihara, Koichi Nishimura, Yuki Nemoto

|Feb 06, 2026
Clinical evaluation of medical and surgical complete responses in metastatic renal cell carcinoma treated with immune checkpoint inhibitor combination therapy.

Kazuhiko Yoshida, Tsunenori Kondo, Junpei Iizuka

|Jan 27, 2026
Non-Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors.

Hiroki Ishihara, Yu-Yu Liu, Riu Yamashita

|Dec 18, 2025
Treatment Profile of First-Line Immune Checkpoint Inhibitor Combination Therapy for Advanced Renal Cell Carcinoma in Patients With End-Stage Renal Disease on Dialysis.

Hiroki Ishihara, Yuki Nemoto, Shinsuke Mizoguchi

|Sep 30, 2025
Impact of starting dose of tyrosine kinase inhibitors on outcomes following combination therapy of immune checkpoint inhibitors with tyrosine kinase inhibitors for previously untreated advanced renal cell carcinoma.

Hiroki Ishihara, Koichi Nishimura, Yuki Nemoto

Pageof 4

Frequent Collaborators

17 joint publications

Toshio Takagi

13 joint publications

Hiroki Ishihara

7 joint publications

Tsunenori Kondo

2 joint publications

Yuki Kobari